Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. - Wikidata - thesis-toulmin - TriplyDB

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

http://www.wikidata.org/entity/Q40457809

about

Role of the tumor microenvironment in mature B-cell lymphoid malignancies Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Adoptive T-Cell Immunotherapy CAR T cells for solid tumors: armed and ready to go?Adoptive cell therapy for sarcoma Engineered T cells for cancer treatment Immunotherapy in acute leukemia Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells Immunotherapy of human cancers using gene modified T lymphocytes.Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.Engineering lymphocyte subsets: tools, trials and tribulations Genetically modified T-cell therapy for osteosarcoma The past, present, and future of adoptive T cell therapy.Supernatural T cells: genetic modification of T cells for cancer therapy.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Improving T cell therapy for cancer.Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis.Immunological research using RNA interference technology.Autophagic Cell Death and Apoptosis Jointly Mediate Cisatracurium Besylate-Induced Cell Injury.Genetic modification of T cells for immunotherapy.Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma Adoptive cellular immunotherapy for childhood malignancies.Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.Design and development of therapies using chimeric antigen receptor-expressing T cells Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".Designing T cells for cancer immunotherapy Hodgkin disease and the role of the immune system.Cellular immunotherapy for high-grade glioma.Ex vivo gene transfer for improved adoptive immunotherapy of cancer.Genetic engineering of T cells for the immunotherapy of haematological malignancies.siRNA and cancer immunotherapy.New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.Adoptive immunotherapy for cancer.

P2860

Q26748775-C9F2E9B3-3F1E-4C6A-90E9-33F56DF8158C Q26773309-EC90F3B3-CB3C-4C67-A5AE-A53FA98D071E Q26782845-EF404963-E22B-4197-AA2D-04F8FD5E2999 Q26825489-EEB994CE-C98B-45FF-A34D-1EB02EB41A1B Q27009541-7FDCE7FA-5E11-4214-B7F3-DF60C87CDAB0 Q33578792-A52AE7FF-CBC1-4DE0-99E9-6FCB70FEE5DE Q33731552-97F9BFC7-0027-4FE7-B85F-EB0FC556D752 Q33801773-3AC093CA-41C2-4495-97D4-3286E1DABBF3 Q34188383-75615A44-5680-4204-AA33-56A8131A04D0 Q34205181-8B1BDB62-102C-4AC6-8220-4196A9E96448 Q35623465-806F3143-EA69-43B9-825F-5EE027D51298 Q35848840-C189BC4C-8B6E-4513-B057-6ADC8CDB42DC Q36007685-4C564A03-9B93-4F4A-BB49-1CDFFC170DB2 Q36059585-663E1CFE-A244-4EE3-AFF1-D1E9AD169621 Q36140986-84501BCF-BEBF-4B9B-A522-C72367EAF9F5 Q36198232-F0365604-528D-4A3D-9813-BF68B2B50C5E Q36306644-6B1190B6-0FBE-4626-96B4-5A00E61A72B2 Q36328805-2854BF9D-2CBB-4FD7-9AEB-AE5539D55DA2 Q36366557-5E40D980-EE94-407C-B6E5-DE015B80DBA1 Q36407236-67B77F8A-778F-42F0-8B9C-1B44A38ECF65 Q36747951-78CBE10D-8CC7-4EF6-9279-8D9E31A1A8BE Q36788606-E19B0787-1A94-4612-B0A1-DFEE892A6898 Q36847070-1BB7D85C-1D18-426F-B531-E1996D10E412 Q36909362-EB79CB6D-B0E1-4592-B01C-B8AE18112485 Q36956269-25AAC3F4-ED60-4686-83CE-D6BD2ECB1A8E Q37008216-C92A6B0B-4CB8-4375-9106-7A962C67E948 Q37058110-E56D07FA-9135-4D88-8B5C-C6496D132155 Q37257207-2DB9619E-5E2F-4AF8-A4E1-7FF41F1859CF Q37262424-45411E15-ED19-4EAC-B77A-886B92F5906A Q37418289-F6750CE6-0E63-4520-85F1-3BAD9DCA01EF Q37450543-C6263203-0EA2-4910-9DB6-16934512D7A4 Q37585288-325CA173-4335-4A47-B17A-E61A5294B879 Q37737817-01411597-D988-46E6-A96E-8E0927241440 Q37850445-20D4A866-4641-443F-956D-5068D6861A91 Q37851972-564F7622-3A12-4021-AB3F-243403A43AA3 Q37854259-2A85234F-278E-4513-B737-D19481047CF4 Q37965815-AE6CEFDE-BC26-41B3-BD2F-D8386C95B898 Q38050504-12598E4E-D554-424E-893F-736846C2BD11 Q38085250-437F2EC9-31AD-4140-8C8B-4191CB770CF4 Q38170496-9AC8CED4-753A-4FB4-AE1D-B5C7D75F3E4E

P2860

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

http://www.wikidata.org/entity/Q40457809

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

@en

type

label

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

@en

prefLabel

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

@en

P1433

Q40457809-4EBD0F72-4A4B-46F8-83AA-ECFE414FC65F

P1476

Q40457809-DD7223D1-064B-4F96-938A-0F89E409BC3D

P2093

Q40457809-02CCC591-3516-43EC-8650-A9F7C4815771

Q40457809-02EC5798-B225-4360-A218-0D1BF0094087

Q40457809-0DAE6E26-562C-4A71-834B-7B8754E6119B

Q40457809-22DE62D1-79B6-4E39-B19D-CF0FB29D27FD

Q40457809-90AE5BA1-F1C3-4F32-878D-3D2732DD03CA

Q40457809-9A34F0DB-65C6-4D9B-9824-C41994BE5B9F

Q40457809-9A59177A-CE44-4C36-BFEF-9E9A06D1ACF6

Q40457809-ABC04C94-B3BB-4C69-9742-4017D7ACA423

P2860

Q40457809-0F78A105-D5EA-49E1-95F9-059021255126

Q40457809-1321D977-CE5E-4BB6-A80C-05807C657569

Q40457809-155B563B-5DD8-457D-9F29-52682E171503

Q40457809-1DFECEB9-CA0C-4A25-83B1-6AACA6F37D97

Q40457809-1E8A042F-F0A9-4892-927C-19E993543B76

Q40457809-239DE70E-C3EE-44F1-94FB-AD9A020AF425

Q40457809-2EFB12AB-DEC9-471D-BE59-4EED41C5139A

Q40457809-2F80EE07-08DF-4E1E-9D3F-AAF4AD15C8B6

Q40457809-34202B78-AC82-4010-A0A1-8D107C226232

Q40457809-3872E7D4-07C9-4FCD-9467-95AA3E5A6CB4

P304

Q40457809-32EC56F9-7B33-4834-9DE6-99BC3F03D07C

P31

Q40457809-B1FDB6E6-136E-424E-940B-4EC854ADF26A

P356

Q40457809-6C6C2EBF-B81A-4EB3-90E5-64B4C97EB028

P407

Q40457809-BFBEC444-6A79-4ADF-9546-9F7BA8920D09

P433

Q40457809-298BEB6E-174B-4FEB-89C3-59F56A73C4C9

P478

Q40457809-3D268EA7-1D03-43E8-B82F-1FEF6BA4C42C

P50

Q40457809-A6645A8C-F397-4F24-87CC-833B25EC502A

P577

Q40457809-3E6055DC-2A0A-47AA-A250-4C2CBE9C14DC

P5875

Q40457809-83EEF8E3-34B4-4ADE-9D55-75476017EF71

P698

Q40457809-D2FA65DA-1E53-46D0-9461-602E8C1C09EB

P921

Q40457809-46D7BE41-DB84-4647-A777-05E43750930E

P932

Q40457809-ED4366A3-A126-4372-9B82-C5E40B686304

P356

BLOOD-2004-08-3337

P1433

P1476

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

@en

P2093

Barbara Savoldo

http://www.w3.org/2001/XMLSchema#string

Cliona M Rooney

http://www.w3.org/2001/XMLSchema#string

Eric Yvon

http://www.w3.org/2001/XMLSchema#string

Ettore Biagi

http://www.w3.org/2001/XMLSchema#string

Gianpietro Dotti

http://www.w3.org/2001/XMLSchema#string

Karin C Straathof

http://www.w3.org/2001/XMLSchema#string

Malcolm K Brenner

http://www.w3.org/2001/XMLSchema#string

Stephane Vigouroux

http://www.w3.org/2001/XMLSchema#string

P2860

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

A system for stable expression of short interfering RNAs in mammalian cells

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

The Fas death factor

Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.

Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.

Gene transfer of Fas ligand induces tumor regression in vivo.

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

P304

4677-4684

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2004-08-3337

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8018932

http://www.w3.org/2001/XMLSchema#string

P698

15713795

http://www.w3.org/2001/XMLSchema#string

P921

P932

1895003

http://www.w3.org/2001/XMLSchema#string